Search results
Showing 976 to 990 of 2185 results for guidelines
NICE's technology appraisal guidance makes recommendations on the use of new and existing medicines and other treatments within the NHS.
Apremilast for treating moderate to severe plaque psoriasis (TA419)
Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults.
Cardiovascular disease prevention: risk assessment (modifiable risk factors) (IND270)
This indicator covers the percentage of people aged 43 to 84 years with a modifiable risk factor who have a recorded cardiovascular disease (CVD) risk assessment score in the preceding 3 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
Rapid tests for group A streptococcal infections in people with a sore throat (HTG531)
Evidence-based recommendations on rapid tests for group A streptococcal infections in people aged 5 and over with a sore throat.
up to 5 years This toolkit helps healthcare providers implement NICE guideline NG247: improving antenatal care, reducing inequalities,...
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas (MIB294)
NICE has developed a medtech innovation briefing (MIB) on AMBLor for identifying low-risk non-ulcerated early-stage cutaneous melanomas .
NICE has developed a medtech innovation briefing (MIB) on FreeStyle Libre for glucose monitoring .
with significant variation between different international and national guidelines. Current practice in the NHS is to give anti-D to all...
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Frequency of application of topical corticosteroids for atopic eczema (TA81)
Evidence-based recommendations on using topical corticosteroids for people with atopic eczema.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Evidence-based recommendations on nintedanib (Vargatef) for treating locally advanced, metastatic or locally recurrent non-small-cell lung cancer in adults.
Our resource planner tool to help you plan for and implement NICE guidance.